Oxford BioTherapeutics Licenses WuXi Biologics’ WuXiBody Platform for Five Bispecific Antibodies
Oxford BioTherapeutics Licenses WuXi Biologics’ WuXiBody Platform for Five Bispecific Antibodies
Shots:
- Wuxi to receive upfront, $450M milestone and royalties on sales from Oxford BioTherapeutics. Oxford to get rights for WuXi Biologics’ WuXiBody platform to develop and commercialize five Bispecific Abs for cancer
- The focus of the agreement is to develop cancer therapies by combining WuXiBody platform with PDL1 Ab with reduction in cost & risk rates
- WuXiBody platform is a bispecific Ab technology with structural flexibility, assess in development of Abs with different valency (2, 3 or 4 binding sites) for multiple therapeutic area
Click here to read full press release/ article | Ref: Oxford Biotherapeutics | Image: Contract pharma